Patients receive a single dose of IV paclitaxel over 3 hours. Additional cycles of paclitaxel will be given at the discretion of the physician.

Patients are followed for second malignancies, disease progression, and survival.

PROJECTED ACCRUAL: A total of 120 patients (40 patients per cohort) will be accrued for this study within 2 or 3 years.

Eligibility

Ages Eligible for Study:

55 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

DISEASE CHARACTERISTICS:

Histologically proven nonhematologic malignancy

PATIENT CHARACTERISTICS:

Age:

55 and over

Performance status:

Zubrod 0-2

Life expectancy:

Not specified

Hematopoietic:

Granulocyte count at least 1,500/mm3

Platelet count at least 100,000/mm3

Hepatic:

Bilirubin less than 1.5 mg/dL

SGOT less than 2.0 times upper limit of normal (ULN)

Renal:

Creatinine no greater than 1.5 times ULN

Cardiovascular:

No uncontrolled or severe cardiovascular disease

Other:

No serious intercurrent medical illnesses that in the judgement of the investigator compromise patient care

No psychiatric conditions that would preclude study

No requirement for antibiotics for active acute infection

PRIOR CONCURRENT THERAPY:

Biologic therapy:

Not specified

Chemotherapy:

At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

No more than one prior chemotherapy regimen allowed

No prior paclitaxel allowed

Endocrine therapy:

Not specified

Radiotherapy:

At least 4 weeks since prior radiation therapy

Surgery:

Not specified

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00003092